Scienmag

APRIL 22, 2021

In February, the researchers introduced […].

Production 84

Production Vaccine Vaccination Protein 84

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccine Vaccination 75

Scienmag

JULY 15, 2021

A new protein-based vaccine candidate combined with a potent adjuvant provided effective protection against SARS-CoV-2 when tested in animals, suggesting that the combination could add one more promising COVID-19 vaccine to the list of candidates for human use.

Protein 52

Protein Vaccine Vaccination Allergies 52

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells.

Allergies 53

Allergies Vaccine Vaccination Gene Therapy 53

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccine 68

Vaccine Vaccination Trials DNA 68

The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. This protein then appears on the surface of the cell and the immune system responds to it.

Vaccine 52

Vaccine Vaccination Allergies Protein 52

Scienmag

JULY 23, 2021

Vaccines against COVID-19, which […].

Antibody 75

Antibody Protein Vaccine Vaccination 75

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. Participants are being randomised to receive two doses of either AZD1222 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine than the saline control.

Vaccine 69

Vaccine Vaccination Trials Immune Response 69

Scienmag

JULY 6, 2021

Studies reveal unprecedented mechanism behind loss of antibody neutralization against this pandemic coronavirus variant of concern Credit: Young-Jun Park, UW Department of Biochemistry Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced by current vaccines or past COVID infections.

Antibody 98

Antibody Protein Vaccination Vaccine 98

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccine 85

Vaccine Vaccination Clinical Trials Clinical Trials 85

Pfizer

SEPTEMBER 28, 2022

5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. 5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. 5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age. 1-adapted bivalent vaccine, non clinical and manufacturing data from the companies’ 10-µg Omicron BA.4/BA.5-adapted

Vaccine 101

Vaccine Vaccination Medicine Clinical Trials 101

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases.

Vaccine 52

Vaccine Vaccination DNA Protein 52

pharmaphorum

FEBRUARY 28, 2021

The FDA has approved emergency use of a third COVID-19 vaccine from Johnson & Johnson’s Janssen Biotech unit, the day after an advisory committee concluded it was safe and effective. Today, FDA issued an emergency use authorization (EUA) for the third vaccine for the prevention of #COVID19 caused by SARS-CoV-2. Janssen’s Ad26.COV2.S

Vaccine 59

Vaccine Vaccination Immune Response Protein 59

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). Vir Biotechnology, Inc.,

Vaccine 59

Vaccine Vaccination Trials Clinical Trials 59

Pfizer

DECEMBER 8, 2022

FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza. INDICATION & AUTHORIZED USE Pfizer-BioNTech COVID-19 Vaccine, Bivalent, (Original and Omicron BA.4/BA.5) AUTHORIZED USE .

Vaccine 81

Vaccine Vaccination Clinical Trials Clinical Trials 81

XTalks

JANUARY 27, 2021

COVID-19 vaccine maker Moderna announced this week that results from a study show that the shot is effective against some of the new circulating variants of SARS-CoV-2. In a news release from Moderna, the company reported that the administration of its COVID-19 vaccine induced antibody titers against both variants.

Vaccine 52

Vaccine Vaccination In-Vitro Protein 52

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada.

Vaccine 52

Vaccine Vaccination Trials Immune Response 52

Scienmag

JUNE 25, 2021

Changes to the ‘spike’ protein explain Alpha’s faster spread, and how the Beta variant evades immune responses, suggesting the need for a booster with an updated vaccine Credit: Bing Chen, PhD, Boston Children’s Hospital New SARS-CoV-2 variants are spreading rapidly, and there are fears that current COVID-19 vaccines won’t (..)

Immune Response 75

Immune Response Vaccine Vaccination Protein 75

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. The institute also led and funded early-stage clinical research into the vaccine candidate.

Vaccine 104

Vaccine Vaccination Development Research 104

Scienmag

MARCH 4, 2021

A deep sequencing study of 747 SARS-CoV-2 virus isolates has revealed mutant peptides derived from the virus that cannot effectively bind to critical proteins on the surface of infected cells and, in turn, hamper activation of CD8+ killer T cells that recognize and destroy these infected cells.

Protein 54

Protein Allergies Vaccination Vaccine 54

Bioengineer

JULY 23, 2021

Intranasal vaccination is needle-free and elicits immunity at the site of infection, the respiratory tract. – There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., Credit: UAB.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.

Vaccine 52

Vaccine Vaccination Allergies Genome 52

The Pharma Data

DECEMBER 17, 2020

Food and Drug Administration (FDA) ’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the agency grant Moderna ’s COVID-19 vaccine emergency use authorization (EUA). A week ago, the FDA granted Pfizer-BioNTech’s COVID-19 vaccine EUA on Friday the day after the same adcom voted 16-1-1.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

Pfizer

JANUARY 27, 2023

In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern.

Research 112

Research Vaccine Vaccination Drugs 112

XTalks

DECEMBER 7, 2020

Past Few Weeks Herald Good News on the Vaccine Front. First came the news from Pfizer and its German partner BioNTech that their mRNA vaccine was 90 percent effective in preventing symptomatic COVID-19 disease. In their trial, some 30,000 patients received either two doses of Moderna’s mRNA-1273 vaccine 28 days apart or placebo.

Vaccine 52

Vaccine Vaccination Development Drugs 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. The BET inhibitor worked by increasing beta-3 tubulin (TUBB3), a protein found in brain metastases.

Vaccine 53

Vaccine Vaccination Research Trials 53

Scienmag

OCTOBER 23, 2020

The technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.

Protein 61

Protein Antibody Scientist Vaccination 61

Scienmag

DECEMBER 9, 2020

A single protein that appears necessary for the COVID-19 virus to reproduce and spread to other cells is a potential weakness that could be targeted by future therapies.

Protein 75

Protein Genetics Allergies Vaccination 75

Scienmag

MAY 13, 2021

The new […].

Immune Response 53

Immune Response Antibody Protein Vaccine 53

The Pharma Data

APRIL 18, 2022

Food allergies and other types of food hypersensitivities affect millions of people in the U.S. and occur when the body’s immune system reacts to certain proteins in food. Reactions to some non-listed food allergens have relatively low prevalence rates, with some as low as single cases. effective Jan.

Allergies 52

Allergies Cosmetics Production Drugs 52

pharmaphorum

AUGUST 12, 2021

The antibody – called CIS43LS – was isolated from the blood of a volunteer who had developed malaria-neutralising antibodies after being dosed with an experimental vaccine, and modified to extend time it would survive in the blood.

Antibody 64

Antibody Vaccination Vaccine Allergies 64

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The combination appears to work by activation of the tumour-suppressing protein p53, they announced. The gene TP53 produces the protein p53, a known tumour suppressor.

Research 52

Research Protein Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. This new study will complement Mymetics’ other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.

Vaccine 40

Vaccine Vaccination Containment Development 40

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines.

Vaccine 40

Vaccine Vaccination Trials Immune Response 40

The Pharma Data

NOVEMBER 16, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Promising HIV Vaccines in Clinical Trials Advancements in preventable therapeutic options for HIV are currently in progress. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

The Pharma Data

JANUARY 4, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. The MOH has secured 6 million doses of the COVID-19 Vaccine Moderna.

Vaccine 40

Vaccine Vaccination Medicine Containment 40